oriahnn (copackaged) Drug Patent Profile
✉ Email this page to a colleague
When do Oriahnn (copackaged) patents expire, and when can generic versions of Oriahnn (copackaged) launch?
Oriahnn (copackaged) is a drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has ninety-eight patent family members in twenty-five countries.
The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this compound. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Oriahnn (copackaged)
Oriahnn (copackaged) was eligible for patent challenges on July 23, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 6, 2029. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for oriahnn (copackaged)?
- What are the global sales for oriahnn (copackaged)?
- What is Average Wholesale Price for oriahnn (copackaged)?
Summary for oriahnn (copackaged)
International Patents: | 98 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for oriahnn (copackaged) |
DailyMed Link: | oriahnn (copackaged) at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oriahnn (copackaged)
Generic Entry Date for oriahnn (copackaged)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for ORIAHNN (COPACKAGED)
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ORIAHNN (COPACKAGED) | Capsules | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | 300 mg/1 mg/ 0.5 mg; 300 mg | 213388 | 1 | 2022-11-03 |
US Patents and Regulatory Information for oriahnn (copackaged)
oriahnn (copackaged) is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of oriahnn (copackaged) is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Expired US Patents for oriahnn (copackaged)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for oriahnn (copackaged)
See the table below for patents covering oriahnn (copackaged) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2383954 | ⤷ Subscribe | |
Japan | 2016513708 | 月経出血過多および子宮類線維腫の処置に使用するための組成物 | ⤷ Subscribe |
Portugal | 1646389 | ⤷ Subscribe | |
Japan | 2003520856 | ⤷ Subscribe | |
South Africa | 200600475 | Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2009062087 | ⤷ Subscribe | |
Canada | 3174571 | METHODES D'ADMINISTRATION D'ELAGOLIX (METHODS OF ADMINISTERING ELAGOLIX) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Oriahnn (copackaged) Market Analysis and Financial Projection Experimental
More… ↓